COVID-19 Real-Time Learning Network

The monoclonal antibody bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.

Our new table visualizes Evusheld and bebtelovimab in vitro neutralization versus various Omicron sublineages, including BQ.1*.

Bivalent boosters provided significant additional protection against symptomatic SARS-CoV-2 infection in persons who had previously received 2-4 monovalent doses, according to this CDC MMWR.

Adults who were prescribed Paxlovid for mild-to-moderate COVID-19 were more than 50% less likely to be hospitalized, according to this CDC MMWR.

Experts discuss clinical observations and other issues related to the current outbreaks of RSV, influenza and COVID-19.

Based on interviews conducted in July, 4% of children aged 6 months–4 years had received ≥1 doses of COVID-19 vaccine, according to this CDC MMWR.